Answers are grounded in this paper and cite their sources.
Toll-like receptor 7 (TLR7) is a pivotal innate immune sensor and an attractive target for antiviral and immunotherapeutic strategies. In this study, a series of triazolo[4,3-a]quinoxaline-4-ol derivatives were rationally designed, synthesized, and evaluated as potential TLR7-targeting ligands. Pharmacophore-based virtual screening of the ZINC and ChEMBL libraries, followed by molecular docking and molecular dynamics simulations, identified compounds 4a, 4d , and 4e as the most promising candidates. These derivatives were successfully synthesized using green chemistry approaches, confirmed by sustainability metrics, and exhibited no cytotoxicity against J774.1 macrophage and L929 fibroblast cell lines at the tested minimum concentrations. Biological assays revealed potent induction of IL-1β, IL-6, and TNF-α, notably, compound 4d exhibited superior activity compared to the benchmark drug imiquimod (IMQ). Density functional theory (DFT) calculations at the B3LYP/6-31G(d,p) level showed small HOMO–LUMO energy gaps (0.129–0.156 eV) and high dipole moments (4.01–12.04 D), supporting their favorable electronic properties for receptor binding. Furthermore, in silico ADMET predictions using the pkCSM platform suggested acceptable theoretical absorption and distribution profiles, alongside low toxicity and no significant CYP inhibition, although in vivo validation is required. Collectively, these findings highlight the potential of compounds 4a, 4d , and 4e as promising early-stage TLR7-targeted immunomodulator agents, while emphasizing the need for further in vivo pharmacokinetic and receptor selectivity studies.
No takes yet. Share an insight, caveat, or question.
Abbasi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: